Table 12_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Table 6_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Table 3_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Table 8_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Table 7_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Association between Weather-Related Factors and Cardiac Arrest of Presumed Cardiac Etiology: A Prospective Observational Study Based on Out-of-Hospital Care Data by Mario Hensel (4778229)

Table 11_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.xlsx by Zeyi Lv (19344178)

Table 10_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Table 9_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

Table 4_Quercetin exhibits multi-target anti-allergic effects in animal models: a systematic review and meta-analysis of preclinical studies.docx by Zeyi Lv (19344178)

EFFECTS OF LONG-TERM ROUX-EN-Y GASTRIC BYPASS ON BODY WEIGHT AND CLINICAL METABOLIC COMORBIDITIES IN BARIATRIC SURGERY SERVICE OF A UNIVERSITY HOSPITAL by Cátia Ferreira da SILVA (6380180)

Reduced Adenosine Uptake and Its Contribution to Signaling that Mediates Profibrotic Activation in Renal Tubular Epithelial Cells: Implication in Diabetic Nephropathy by Catalina Kretschmar (848445)

Table_2_Gestational Weight Gain and Its Effects on Maternal and Neonatal Outcome in Women With Twin Pregnancies: A Systematic Review and Meta-Analysis.docx by Wei Zhong (284774)

“…Mothers with inadequate weight gain had increased risk for gestational diabetes mellitus (OR 1.19; 95% CI: 1.01, 1.40) and decreased risk for gestational hypertension (OR 0.58; 95% CI: 0.49, 0.68) and cesarean section (OR 0.94; 95% CI: 0.93, 0.96). …”

Table_3_Gestational Weight Gain and Its Effects on Maternal and Neonatal Outcome in Women With Twin Pregnancies: A Systematic Review and Meta-Analysis.docx by Wei Zhong (284774)

“…Mothers with inadequate weight gain had increased risk for gestational diabetes mellitus (OR 1.19; 95% CI: 1.01, 1.40) and decreased risk for gestational hypertension (OR 0.58; 95% CI: 0.49, 0.68) and cesarean section (OR 0.94; 95% CI: 0.93, 0.96). …”

IFT46 and IFT52 are important for IFT B protein stability, while IFT88 is not. by Elizabeth A. Richey (312079)

Immunofluorescence analysis of lumbar spinal cord sections at 3 months after spinal cord transection. by Jose A. Corleto (841164)

Supplementary figure 2 from Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling by Whitney S. Henry (14928330)

Quantification of cell apoptosis and survival by flow cytometry in CsA-treated HK-2 cells: Effect of GADD45G knockdown. by Gyu-Tae Shin (5819249)

Data_Sheet_1_Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis.PDF by Xiehui Chen (9538275)

“…In comparison to the control group, the data demonstrated that SGLT-2i is related with a decreased incidence of composite outcome (HR: 0.77, 95% CIs: 0.73–0.81, I² = 0%, P < 0.01), CV death (HR: 0.87, 95% CIs: 0.81–0.94, I² = 3%, P < 0.01), all-cause mortality (HR: 0.90, 95% CIs: 0.84–0.96, I² = 10%, P < 0.01), and hospitalization due to HF (HHF) (HR: 0.70, 95% CIs: 0.66–0.75, I² = 0%, P < 0.01). …”

Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017 by Maria Gańczak (8519883)

“…DALYs due to non-communicable diseases (NCDs) decreased slightly (2.0%; 0.1–4.6). In 2017, Poland performed better than CE as a whole (ranked fourth for YLLs, sixth for YLDs, and fifth for DALYs) and achieved greater reductions in YLLs and DALYs than most CE countries. …”